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U.S. Pat. No. 4,406,878 discloses a method for form

ing radiographic images of a body portion such as a
human organ by introducing into the body portion a
water-insoluble, non-water swellable iodinated polymer

BIODEGRADABLE, LOW BIOLOGICAL
TOXICITY RADIOGRAPHIC CONTRAST
MEDIUM AND METHOD OF X-RAY IMAGING

having an iodine content in excess of 35 wt % and then

X-ray imaging the organ. The polymer is composed of
a repeating organic unit forming the backbone chain of
the polymer, and iodinated aromatic groups and hydro
philic groups which stick out from the backbone chain.
The diameter of the polymer beads can be as high as
1,000 microns. The hydrophilic groups containing the

TECHNICAL FIELD
This invention relates to a new radiographic contrast

medium for computerized tomographic (CT) imaging
of portions of the subject’s body. The medium disclosed
herein provides a polymer comprising a speci?ed par
ticulate size compounds previously used as water-solu

iodine are attached to the backbone of the polymer by a

ble contrast agents. The polymers are designed so that

linking group which may be an ester, ether, amide,
thioester, carbonate, carbamate, sul?de and the like.

they precipitate into particles of a speci?c size which
can be taken up by organs such as the liver or spleen. In
addition, the present medium can also be utilized as a
vascular contrast agent due to its extensive retention in
the blood vessels.

The particle size of the beads may vary over a very
broad range. The medium is therefore very inef?cient
and expensive to use since large amounts are required
for a small proportion of the beads to reach a particular

target tissue.
BACKGROUND ART
Iodinated compounds have been used in colloidal
20
The ?eld of medical radiography is well known. This
form in cholecystography. U.S. Pat. No. 1,858,142 dis
is an extremely valuable tool for the early detection and
closes the production of a mono- and di-alkali metal salt
diagnosis of various diseases of the human body. Differ
of tetraiodophenolphthalein in colloidal form. U.S. Pat.
ent parts of the human body such as cavities and soft
No. 1,984,404 describes a similar composition compris
tissues of various organs and blood vessels evidence low
ing an alkali-metal salt of tetraiodophenolphthalein. The
X-ray radiation absorption. Thus, radiographing these
compound is provided for oral administration for the
body portions is difficult. To overcome this hurdle
imaging of the hapatobiliary tract.
contrast agents which are opaque to X-ray radiation
Water-soluble contrast agents have drawbacks such
have been used.
as their inherent hyperosmolality. Non-ionic agents
Several inorganic materials have been used as con
were developed as a means to reduce hyperosmolality
trast agents. Examples of these are bismuth subnitrate,
since they have about half the osmolality of their corre
bismuth subcarbonate, and barium sulfate, among oth
sponding ionic monomers.
ers. U.S. Pat. No. 4,709,703 discloses a method of imag
Particulate contrast agents were also developed be
ing an organ’s tissue by perfusion with beads made of a
cause the particles make almost no contribution to the
metal or tungsten of 15-18 micron diameter.
35 osmotic pressure of a medium. Accordingly, the use of
Iodinated organic agents have also been used as con
particulate contrast agents affords the possibility of
trast agents since the iodine atom is an effective X-ray
administering high iodine content materials which lack
absorber. Among these are iodinated oils, such as ethyl
the ?uid and ion shifts associated with water-soluble
iodo-phenylundecylate, used ‘ for myelography, and
agents. An additional advantage of particulate contrast
water-soluble, iodinated organic compounds used for 40 agents is the fact that their increased molecular size has
X-ray visualization of the gastrointestinal tract.
no signi?cant affect on the distribution volume thereof.
Water-soluble, iodinated organic compounds, how
That means that in fact there is more of the X-ray
ever, can cause extremely severe side effects when used
opaque component retained in the same volume. More
as a gastrointestinal contrast agent in dehydrated pa
over, the particulate contrast agents are initially re
tients, especially infants. For this reason, these materials 45 tained exclusively within the vascular space. Only if
have become quite controversial and some radiologists
they are of the correct size will they be phagocytized
no longer use such agents in the gastrointestinal tract
into the cellular space of an organ. Thus, for an initial

(See, Radiographic Contrast Agents, Miller et al, p 169,
University Park Press, Baltimore, Md. 21202 (1977)).
Water-insoluble, iodinated organic polymers have
been used as contrast agents, as well. Such is the case of

the product disclosed in British Patent Speci?cation
No. 1,400,985. This patent describes polymers contain

period after their administration particulate contrast
50

agents are useful for conducting blood ?ow and volume
studies without using radioisotopes or any complex
compartmental analysis necessary to account for any
exodus of the particle into interstitial spaces.
Violante et a1, Invest. Radiol. ~ l5(6):S329-S334

ing iodine-substituted aromatic groups which are
(November-December 1980), Korman et a1, Invest.
readily swellable in water to yield a gel. The iodine 55 Radiol. 19:133 (1984), and Sands et al (Invest. Radiol.
content of the polymers is between 20 and 35 wt %.
22(5):408—4l6 (May 1987) disclosed particulate contrast
Biodegradable microspheres labeled with X-ray ab
agents having diameters in the range of two microns
sorbent material have been used as contrast agents for
and smaller. The agents are iodinated aromatic struc

the visualization of arterial circulation and the diagnosis
tures which are esteri?ed and amidized with methanol
of pulmonary embolism and other diseases in humans.
and ethanol such as ethyl esters of iothalamic and
iodipamic acid. These compounds are preincubated in
U.S. Pat. No. 4,680,171 provides a method of visualiz
human serum albumin to overcome in vivo particle
ing the arterial circulation of a person by administering
aggregation and embolization. Similar compounds are
microspheres bearing an X-ray absorbent material, and
used as antimicrobial agents in particulate form (see,
subsequently X-raying the area of arterial circulation
sought to be visualized. The medium utilized in this 65 U.S. Pat. No. 4,783,484).
However, the development of suitable particulate
patent has microspheres of a 9-100 micron diameter.
contrast agents has not been forthcoming because of the
Examples of materials utilized in the prior art patent are
dif?culties involved in their development. The size and
albumin and starch.
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up preferentially by a portion of the body which is
desired to be imaged by means of X-ray technology.
This lowers the background noise and permits to obtain
better contrast picture of the body portion.
The present invention provides a biodegradable, low

shape of the particles must be such that they do not
cause embolism in the capillaries, and in vivo particle
aggregation must be avoided to prevent the occurrence

of embolism. The uptake of the contrast agent by the
desired tissue must be maximized while at the same time

biological toxicity, particulate radiographic contrast
medium which comprises biodegradable polymeric

permitting its quick removal within a reasonable period
of time. Moreover, any contrast agent to be useful and
obtain approval for use in‘ humans must have substan

spheres of estimated average molecular weight about

tially reduced biological toxicity.

104 to 108 daltons and average diameter about l0—l,000

Accordingly, there still is a need for an improved

nanometers or about 0.0l-l.0 micron and carrying an at

X-ray imaging agent having the above characteristics.

least radiographic contrasting amount of a radiographi
cally opaque element.
In a preferred embodiment of the invention, the bio
degradable polymeric spheres of the invention have an
average molecular weight of about 105 to 107 daltons,
and still more preferably about 50,000 to 200,000
daltons. In another preferred embodiment the average
diameter of the spheres is about 10-900 nanometers or

DISCLOSURE OF THE INVENTION
This invention relates to a biodegradable, low biolog

ical toxicity, particulate radiographic contrast medium
which comprises
biodegradable polymeric spheres of estimated aver
age molecular weight about 105 to 107 daltons and

average diameter about l0-l000 nanometers or
about 0.1-0.9 microns, more preferably about 10 to 800
about 0.01-l.0 micron and carrying an at least 20 nanometers or about 0.0l-0.8 micron, and still more

radiographic contrasting amount of a radiographi
cally opaque element.
Also disclosed herein is an imaging composition,

preferably about 10-500 nanometers or about 0.0l-0.5
microns.
In the most preferred embodiment of the contrast

which comprises

medium, the average diameter of the spheres is about

a radiographically-detectable amount of the contrast

50-500 nanometers or 0.05-0.l micron, and more pref
erably about 100-200 nanometers or 0.1-0.2 micron.
The present contrast medium is particularly suited for
imaging of the vascular regions of the body as well as
organs such as the liver and spleen because of the spe
ci?c range of the diameter of the spheres. Because of the

medium of this invention; and

a pharmaceutically-acceptable, substantially X-ray
transparent carrier.
This invention also relates to a method of obtaining a

tomographic image of a body portion of a subject,

which comprises

diameter range of the polymeric spheres the present

administering to the subject a radiographically
detectable amount of the biodegradable, low-tox

contrast medium may be phagocytized by, e.g., the

icity radiographic medium of this invention;
allowing for the spheres to be taken-up by the body
portion; and
X-ray imaging an area comprising the body portion.
Still part of the invention is another method of im
proving the contrast of a tomographic image of a body

portion of the subject which comprises

35

Kupffer cells of the liver and by the spleen. Since the
present contrast medium comprises particulate material
it, in fact, delivers a higher content of the radiographi
cally opaque element than the corresponding soluble or

non-polymeric materials.
The present contrast medium is especially well suited
for enhancement of liver and spleen images because it is

administering to the subject a radiographically
detectable amount of the biodegradable, low-tox

substantially not eliminated through the kidneys. Thus,

X-ray imaging an area comprising the body portion.

thus be safely used in this large group of patients, i.e.,
renal failure patients.
In another preferred embodiment, the polymeric
spheres may be loaded with the radiographically

it can be effectively used in renal failure patients. One of
the
drawbacks of water-soluble contrast media is that,
icity radiographic medium of this invention;
in renal failure patients, toxic levels of the agent may
allowing for the spheres to be selectively taken-up by
45 build up in the body. The present contrast media can
the body portion; and

A more complete appreciation of the invention and
many of the attendant advantages thereof will be
readily perceived as the same becomes better under

stood by reference to the following detailed description
when considered in connection with the description of

opaque element in order to optimize the utilization of

the agent. That is, the higher the radiographically

the best mode for carrying out the invention and the

opaque element content of the spheres the lesser the

examples. Other objects advantages and features of the

amount of contrast medium necessary to obtain a suit

able X-ray image of a body portion and the higher the
present invention will become apparent to those skilled
55 contrast of the resulting picture.
in the art from the following discussion.
The particles of the present medium are biodegrad
BEST MODE FOR CARRYING OUT THE
able which means that they can be chopped up into
INVENTION
smaller molecules and excreted from the body within a
suitable period of time after administration. Typically,
This invention arose from the desire of the inventors
to improve on prior art products suitable for use as 60 the polymeric spheres are at least partially hydrolyzed
by enzymes which occur in the body prior to excretion.
radiographic contrast agents for imaging speci?c areas
’Examples of these enzymes are esterases, amidases,
of the animal body.

proteases, pseudocholinesterase, lysozyme, elastase and
Computerized tomography (CT or CAT) scanning is
collagenase. In addition, some of the polymers are also
an imaging technique which utilizes X-rays to produce
tomographic images of the body’s internal structures. 65 hydrolyzable at different pHs encountered in the body.
Because they are biodegradable the polymeric spheres
Contrast agents used for this purpose must be capable of
attenuating X-rays. Contrast agents which are ex
tremely useful are those which are designed to be taken

are not retained for extended time periods in the organs
into which they are taken up.

5
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Moreover, the present contrast medium is substan

tially non-biologically toxic, and can, therefore, be ad
ministered in amounts as large as needed, including to
humans.

6

onic acid, and/or iocetamic acid, analogues thereof and
derivatives thereof with an aminated compound.
Preferred hydroxylated compounds are lactate, hy

droxybutyrate, and hydroxyvalerate. However, others

In one preferred embodiment the contrast medium of 5 may also be utilized. Derivatives thereof, particularly
active derivatives reacting with carboxyl groups, may
the invention comprises a polymer which is selected
also be utilized. Examples are epoxides, and the like.
from the group consisting of polyesters, polyamides,
Preferred aminated compounds are glycine and sar
polycarbonates, polycarbamates, and polyureas, deriva
cosine. However, others are also suitable. Active deriv
tives thereof, analogues thereof and pharmaceutically
10 atives thereof are also useful such as aziridines and the
acceptable salts thereof.
like.
Typical polyesters are succinates, acrylates, esters of
The biodegradable, low biological toxicity, particu
(C2—C2o)a1kyl mono- and di~acids with (C2—C30)alkyl,
late radiographic contrast medium of the invention,
alkenyl, alkynyl or (C6-C30)aryl hydroxylated com
may further comprise
pounds, derivatives thereof, analogues thereof and co

polymers thereof with other monomers. Preferably, the rd 5 an additive selected from the group consisting of
colorants, preservatives, stability enhancing agents,
hydroxylated compounds and/or the other monomers

have covalently attached thereto the radiographically
opaque element(s).

Examples of polyamides are acrylamides, (C2-C30)al
kyl, alkenyl or alkynyl acrylamides, amides of (C2-C3.
0)alkyl, alkenyl or alkynyl mono- or di-acids or (Cg-C3.
o)aryl mono- and di-acids with (Cz—C30)alkyl, alkenyl or

alkynyl or (C6-C30)aryl aminated compounds, deriva
tives thereof, analogs thereof and co-polymers thereof

biological transport enhancing agents, suspending
agents, osmotic agents, salts and the like.
Examples of colorants are any FDA approved dyes.
Examples of preservatives are benzoic acid and the like.

Examples of stability enhancing agents are povidone
and polyvinyl alcohol. Examples of biological transport
enhancing agents are povidone and the like. Examples
of suspending agents are dextran and dextrose. How

with other monomers. Preferably, the aminated com 25 ever, other colorants, preservatives, stability enhancing
agents, biological transport enhancing agents, suspend
pounds and/or the monomers have bound thereto the

radiographically opaque element(s).
The derivatives may comprise, in addition, substitu
ents such as halogen, (C1-Cg)alkyl, alkenyl or arometic
or heterocyclic. However, other derivatives which do
not interfere with the activity of the spheres in a nega
tive fashion may also be utilized.
The analogues may have a similar chemical formula

ing agents, osmotic agents and salts may also be utilized
as is known in the art. All these additives are added in
amounts known in the art and are prepared by methods
also known in the art.

The radiographically opaque element utilized for the
practice of this invention may be selected from the

group consisting of iodine, bromine, samarium, erbium,

and other lanthanides. These are known in the art as are
but different conformation, substitutions of one mono
mer, acid, or hydroxylated or aminated compound for 35 the methods for incorporating them into monomeric

and polymeric organic molecules. (Ber 28:1603 (1895)

another, and the like.
In another preferred embodiment of the invention the
radiographically opaque element may be added to the

Classen a Lok; Morgan, P. W., “Linear Condensation
Polymers from Phenolphthalein and Related Com

polymeric spheres after they have been formed. This

pounds” J. Polymer Sc. 2:437-459 (1964)).

In a most preferred embodiment of the invention the
can be attained by methods known in the art. (May 40
radiographically opaque element is iodine.
berry, W. E., and Hockert, T. J., “Kinetics of Iodin
In another preferred aspect of the invention the ra
ation”, J. Biol. Chem. 245: 697-700 (1970); Thorell, J. I.
diographically opaque element is covalently bound to
and Johensson, B. G., “Enzymatic Iodination of Poly
the polymer. However, it may also be loaded into the
peptides with I-l25 to High Speci?c Activity”, Bio

chem. Biophys. Acta. 251:363-369 (1971)).
The mono- and di-acids, the hydroxylated com

polymeric spheres by methods known in the art. (May
berry, W. E. and Hockert, T. J., “Kinetics of Iodin
ation”, J. Biol. Chem. 245: 697-700 (1970); Thorell, J. I.
and Johensson, B. G., “Enzymatic Iodination of Poly

pounds, the aminated compounds and the monomers
utilized for the manufacture of the present biodegrad
peptides with I-l25 to High Speci?c Activity”, Bio
able polymeric spheres are prepared by methods known
in the art which need not be repeated herein. (Krewter, 50 chem. Biophys, Acta. 251:363-369 (1971)).
Typically, the radiographically opaque element is
J. “Evaluation at Nanoparticles as Drug-Delivery Sys
present in the polymeric spheres in an amount of about
tems. I: Preparation Methods”, Pharm. Acta. Helv.
10 to 90 wt % of the polymer, more preferably about 30
58:196-209 (1983)).

The co-polymers encompass typically, co-polymers

to 75 wt %, and still more preferably about 40 to 60 wt

with monomers such as tetraciodophenolphthalein,

%.
The radiographic contrast medium of the invention
may also be provided as an imaging composition, com

iocetamic acid, iodoalphionic acid, iopanoic acid, io
phenoxic acid, and ipodate. However, other monomers
known to be pharmaceutically acceptable and substan
tially biologically non-toxic are also suitable.

A particularly preferred polyester is that which is
formed from an acrylate and/or succinate, analogues
thereof or derivatives thereof with an hydroxylated
compound. Also suitable are esters of malonate, male

prising
a radiographically-detectable amount of the contrast

medium of the invention; and

a pharmaceutically-acceptable substantially X-ray
transparent carrier.

The radiographic contrast agent of the invention may
be provided either in a dry or liquid state, depending on
may also be utilized within the con?nes of this inven 65 the type of carrier added to the polymer. For example,
in the dry state the polymeric spheres may be com
tion.
pounded with a dry binder and provided for instance in
A particularly preferred polyamide is one formed
tablet or powder form. In the liquid state, which is a
from tetraiodophenolpthalein, iopanoic acid, iodoalphi

ate, and/or glutarate. However, other types of esters

7
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preferred state of the present radiographic contrast

of the body may be visualized. Thereafter, particularly

medium for introduction into the body of the test sub

after 10 minutes the polymeric spheres start to be taken
up by speci?c organs such as the liver and/or the spleen
and may be utilized for the imaging of these areas. This
is of particular importance and utility in cases of renal
failure when the retention in these organs of the con

ject, the polymeric spheres are suspended in an aqueous
liquid carrier as particulate, water-insoluble, nonwater
swellable beads.

Examples of solid carriers are lactose, povidone, and
the like. Examples of liquid carriers are solutions of
normal saline and 5% dextrose in water. However,
others may also be utilized herein.
In another embodiment of the invention, the radio~
graphic contrast medium is provided as a surgical ele

trast agent is prolonged.
Also provided herein is a method of improving the
contrast of a tomographic image of a body portion of a

subject, which comprises
administering to the subject a radiographically
detectable amount of the biodegradable, low toxic
ity radiographic medium of this invention; de
scribed above or a composition comprising it;

ment comprising a surgical substrate as a carrier, e.g., a

surgical instrument, dressing, suture or implant carrying
a radiographically effective amount of the radiographic

allowing for the spheres to be selectively taken-up by
the body portion; and
X-ray imaging an area comprising the body portion.

contrast medium. The manner in which these may be

applied to the body is known in the art and need not be
further described herein. The amounts of radiographic
contrast medium delivered to the body are similar to

In general, these steps may be conducted as described

those provided either orally or systemically.
In a preferred embodiment of the invention the radio 20

graphic contrast medium consists essentially of the bio

above. Because of their particular molecular weight and
diameter, the spheres are selectively taken-up by organs
such as the liver and spleen. The medium or imaging
composition of the invention can also be utilized for the

degradable polymeric spheres carrying the radiographi
cally opaque element.

visualization, in the period immediately following ad

Also part of this invention is a method of obtaining a

ministration thereof, of the vascular portions of the
body. In addition, because the spheres are substantially

tomographic image of a body portion of a subject,

which comprises

not eliminated by the kidneys, they are safe to use in

administering to the subject a radiographically
detectable amount of the biodegradable, low-tox
icity radiographic medium of this invention;
allowing for the spheres to be taken-up by the body
portion; and
X-ray imaging an area comprising the body portion.

renal failure patients.
Having now generally described this invention, the
same will be better understood by reference to certain

speci?c examples, which are included herein for pur
poses of illustration only and are not intended to be

limiting of the invention or any embodiment thereof,
unless so speci?ed.

The administration of the radiographic contrast me

dium is conducted by methods known in the art. Pre
ferred is intravenous administration but the medium 35
may be administered by other routes. Examples are oral,
intraarterial and intracatheter routes. Other routes of
administration are also possible, such as subcutaneous

EXAMPLES

Example 1: Intravenous Contrast Agent
The present agent is a new reticuloendothelial

specific intravenous contrast agent for enhancement of
liver and spleen at CT scanning. A polyester of tetraio
dophenolphthalein (TIP) was prepared by reacting a

administration. Typically, the contrast medium of the
invention is administered in an amount of about 1 to 500

milligrams/kg of body weight and more preferably
about 10 to 20 milligrams/kg of body weight. However,

solution of sodium TIP in 0.1 M borate buffer contain

ing various quantities of dextran with succinyl chloride

other amounts may also be utilized.

dissolved in dichloroethane. The succinyl chloride solu
After the administration of the contrast agent there is
a waiting period so that the polymeric spheres may be 45 tion is added dropwise to the stirred TIP solution and
the emulsion polymerization reaction is allowed to con
taken-up by the target body portion desired to be im
tinue until the blue color in the TIP solution has com
aged. This period may extend for about 2 to 60 minutes,
pletely disappeared and given way to an off white sus
and in some instances for up to 4 hours. However, this
pension. The dichloroethane is removed under reduced
waiting period depends on the characteristics of the

particular polymeric material contained in the contrast
agent. An artisan would know based on the characteris
tics of the polymer how to close each individual type of

polymer encompassed by this invention.
The X-ray imaging step may be conducted by well
known techniques and utilizing commercially available
X-ray apparatuses. The visualization of the thus ob
tained X-ray image may be conducted also by well
known techniques including the use of a conventional

X-ray sensitive phosphor screen-silver halide photo
graphic ?lm combination, various electrophotographic

50

pressure and the resultant product is gently centrifuged
for 15 min (and washed twice in a similar manner) to

remove large aggregrates. The resulting suspension is
then centrifuged at high speed and the sedimented
nanoparticles are washed twice with water. A portion
55 of the nanoparticles are dried under vacuum for deter

mination of yield. The nanoparticles are then suspended
in 5% dextrose in water (DSW) prior to administration.
The polyester of TIP is about 58% iodine by weight and
precipitates as a monodisperse suspension with a mean
60 particle diameter of 200 nm.

techniques such as xeroradiography and other radio
graphic visualization techniques such as computerized

Example 2: CT Imagining with Agent

axial tomography (CAT or CT) and ionographic tech

CT images of a group of rabbits injected with the
agent demonstrated marked and selective enhancement

niques.

Preferred is the X-raying by computerized axial to 65 of liver and spleen (greater than 100 HU), which gradu
mography or CAT.

Typically, in the period immediately following the
administration of the contrast agent the vascular areas

ally declined over a period of 2-3 weeks.
No evidence of renal concentration or elimination
was encountered.

9
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7. The biodegradable, low biological toxicity, partic

Example 3: Determination of Other Effects
Serial blood samples obtained for some 16 days fol
lowing the administration of contrast agent revealed no
abnormalities in liver enzymes, or in bilirubin, BUN,
creatinine or electrolytes.

ulate radiographic contrast medium of claim 24,
wherein
the average diameter of the spheres is about 50-500

Radiolabeled TIP polymer con?rmed the selective
accumulation of the agent in the liver and spleen, with
less than 1% in the bone marrow.
Radioactive tracer followed in feces indicated biliary
elimination of the agent.

ulate radiographic contrast medium of claim 7, wherein
the average diameter of the spheres is about 100 to

nanometers.

8. The biodegradable, low biological toxicity, partic
200 nanometers.

9. The biodegradable, low biological toxicity, partic
ulate radiographic contrast medium of claim 24, further

comprising

No radioactivity was recovered in the urine.

an additive selected from the group consisting of

This polymer is expected to undergo biodegradation
upon hydrolysis of its ester linkages to TIP, a previ
15
ously used contrast medium of low toxicity.
The invention now being fully described, it will be

colorants, preservatives,

stability enhancing

agents, biological transport enhancing agents, sus
pending agents, osmotic agents and salts.
10. The biodegradable, low biological toxicity, par

apparent to one of ordinary skill in the art that many
ticulate radiographic contrast medium of claim 24,
changes and modi?cations can be made thereto without
wherein
departing from the spirit or scope of the invention as
the radiographically opaque element is selected from
20
said forth herein.
the group consisting of iodine, bromine and lantha
We claim:
nides.
1. A biodegradable, low biological toxicity, particu

11. The biodegradable, low biological toxicity, par
late radiographic contrast medium, comprising
ticulate radiographic contrast medium of claim 10,
biodegradable polymeric spheres of estimated aver 25 wherein
age molecular weight about l05 to 107 daltons,
the radiographically opaque element is iodine.
average diameter about lO-l,000 nm or about
12. The biodegradable, low biological toxicity, par
0.0l-l.0 micron, said spheres carrying an at least

ticulate radiographic contrast medium of claim 24,
wherein

radiographic contrasting amount of a radiographi
cally opaque element and said polymeric spheres
have a polymer backbone made up of polymerized

the radiographically opaque element is covalently
bound to the polymer.

monomer radiographically opaque units or said
13. The biodegradable, low biological toxicity, par
polymeric spheres are a copolymer which has a
ticulate radiographic contrast medium of claim 24,
backbone of monomer radiographically opaque
wherein
units and other monomers that is copolymerized. 35
the radiographically opaque element is present in an
2. The radiographic contrast medium of claim 24,
amount of about 40 to 90 wt % of the polymer.
wherein
14. The biodegradable, low biological toxicity, par
the polymer is selected from the group consisting of
ticulate radiographic contrast medium of claim 24, con

polyesters, polyamides, polycarbonates, polycarba

mates and polyureas, derivatives thereof, analogues
thereof, co-polymers thereof with other monomers
and pharmaceutically acceptable salts thereof.

40

sisting essentially of
the biodegradable polymeric spheres.
15. An imaging composition, comprising
a radiographically-detectable amount of the contrast

3. The biodegradable, low biological toxicity, partic

medium of claim 24; and

ulate radiographic contrast medium of claim 2, wherein
the polymer is a polyester.
45

4. The biodegradable, low biological toxicity, partic

a carrier.

16. The imaging composition of claim 15, comprising
about 1 to 20 wt % of biodgradable polymeric

spheres.

ulate radiographic contrast medium of claim 3, wherein
the polyester is a succinate or acrylate ester of a

17. The biodegradable, low biological toxicity, par

(C2-C30)alkyl, alkenyl or alkynyl mono- or di-acid,

ticulate radiographic contrast medium of claim 3,

or a (C3—C30)aryl mono- or di-acid with a (C2 50 wherein

C30)alkyl, alkenyl or alkynyl or a (C6—C30)aryl

the polyester is derived from tetraiodophenolphthal
ein, analogs thereof or copolymers thereof.
18. The biodegradable, low biological toxicity, par
ticulate radiographic contrast medium of claim 5,

hydroxylated compound, derivatives thereof, ana
logues thereof or co-polymers thereof.

5. The biodegradable, low biological toxicity, partic
ulate radiographic contrast medium of claim 2, wherein
the polymer is a polyamide.

55

wherein

6. The biodegradable, low biological toxicity, partic

the polyamide is a polyamide of tetraiodophenol
phthalein derivative, analogs thereof or copoly

ulate radiographic contrast medium of claim 5, wherein
the polyamide is a polyamide of a (C2-C30)alkyl,

19. The biodegradable, low biological toxicity, par

mers thereof.

ticulate radiographic contrast medium of claim 10,
wherein
the radiographically opaque element is iodine in a

alkenyl or alkynyl mono- or di-acid or a (C8-C30)a

ryl mono- or di-acid with a (Cz-Csohlkyl, alkenyl
or alkynyl or a (C6-C3o)aryl aminated compound,
derivatives thereof, analogues thereof or co

tetraiodophenolphthalein derivative.
0

polymers thereof.
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